PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL'36) in Patients Experiencing Acute Schizophrenia.
- DOI
- 10.1007/s40263-026-01317-5
- Published
- 2026 Sep
- Container
- CNS drugs
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40263-026-01317-5,
title = {PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL'36) in Patients Experiencing Acute Schizophrenia.},
author = {Wieczorek M and Waszkiewicz N and Gromniak-Haniecka E and Réthelyi JM and Pustovoyt M and Filts Y and Blazhevych Y and Matłoka M and Janowska S and Łapińska B and Rudzki PJ and Jaźwiec R and Sierzputowska-Prarat J},
year = {2026},
journal = {CNS drugs},
doi = {10.1007/s40263-026-01317-5},
url = {https://doi.org/10.1007/s40263-026-01317-5}
}RIS
TY - JOUR TI - PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL'36) in Patients Experiencing Acute Schizophrenia. AU - Wieczorek M AU - Waszkiewicz N AU - Gromniak-Haniecka E AU - Réthelyi JM AU - Pustovoyt M AU - Filts Y AU - Blazhevych Y AU - Matłoka M AU - Janowska S AU - Łapińska B AU - Rudzki PJ AU - Jaźwiec R AU - Sierzputowska-Prarat J PY - 2026 JO - CNS drugs DO - 10.1007/s40263-026-01317-5 UR - https://doi.org/10.1007/s40263-026-01317-5 ER -
APA
M, W., N, W., E, G., JM, R., M, P., Y, F., Y, B., M, M., S, J., B, Ł., PJ, R., R, J., & J, S. (2026). PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL'36) in Patients Experiencing Acute Schizophrenia.. CNS drugs. https://doi.org/10.1007/s40263-026-01317-5
Source records
- pubmed · retrieved 2026-09-26T05:59:38.949Z
- europe-pmc · retrieved 2026-09-26T05:59:38.964Z